Why TEVA’s Cannabis Inhaler is a Big Deal
January 4th, 2017
News, Top Story
A metered-dose TEVA cannabis inhaler is about to be revealed to the world by TEVA Pharmaceutical Industries Ltd. The Israeli multinational generic drug manufacturer has teamed up with Syqe Medical to circulate the pocket-sized selective-dose cannabis inhalers, which have already been administered to Rambam Health Care Campus patients in Haifa for more than a year.
Currently, Israel cannabis is used by approximately 25,000 Israeli patients, as part of the country’s formal medical marijuana program. This program was approved by the Ministry of Health in 1992, following the publication of research conducted by discoverer of the endocannabinoid system, Dr. Raphael Mechoulam. Medical cannabis research and development is contributing to the innovation of products that deliver marijuana, like the TEVA cannabis inhaler.
TEVA Israel’s CEO, Avinoam Sapir, said “TEVA Israel is entering the field of medical cannabis out of a deep commitment to patients coping with pain.” Distribution and cooperation for the first-in-class device are currently awaiting approval from the Ministry of Health. However, the Syqe Inhaler™ will likely be given the go-ahead for home use next year.
Advanced Level of Precision
Childproof and designed to deliver metered doses of cannabis with 100 microgram precision, the TEVA cannabis inhaler is predicted to become the most versatile drug delivery product of its time. The fascinating little device dispenses Tetrahydrocannabinol (THC) through “preloaded cartridges.” Produced with 3D printing equipment, the pain-relieving apparatus detects the user’s breath, before releasing an accurate amount of raw, whole-plant cannabis.
As if that wasn’t impressive enough, Israel cannabis products have been fashioned to correspond with smartphone software. By monitoring the outcome of medical cannabis medication, both patients and researchers can better understand the effectiveness of vaporizers. Philip Morris International Inc. has invested $20 million in the TEVA cannabis inhaler, which has raised $30 million in financing through Syqe Medical so far.
Israel is a Medical Marijuana Pioneer
The non-medicinal use of Israel cannabis might not be legal, but the country boasts a blossoming medical marijuana industry. In August, Shaare Zedek Medical Center’s chief of pediatric neurology, Dr. Adi Eran, was granted a government permit to conduct a medical cannabis clinical trial. The trial will focus on the positive health benefits of marijuana when prescribed to autistic children and adults.
It is not just this achievement that has contributed to the nation’s pioneering approach to cannabis research, however. Approximately 70 Israel-based companies are actively promoting analysis garnered by Israeli organic chemist and professor of Medicinal Chemistry, Prof. Raphael Mechoulam. His research has extended for decades and it shines a light on the positive consequences cannabis has on the brain, digestive system, and bones.
Israel cannabis start-ups are looking into mass marketing opportunities in the United States, what with eight states being given the green light to legalize medical and recreational cannabis use. Furthermore, 23 states have permitted the medical use of marijuana to some extent. Be that as it may, marijuana is classified as a Schedule 1 controlled substance in the U.S. and since the U.S. Drug Enforcement Administration believes there is a “high potential for abuse” linked with plant use, revisions to cannabis classification were recently dismissed.
Lawmakers in the U.S. and Canada ought to take inspiration from technology like the TEVA Cannabis Inhaler, according to cannabis campaigners.
TEVA Sparks a Trend
As one of the 15 biggest pharmaceutical companies worldwide, TEVA Pharmaceutical Industries is an authoritative leader in the Israel cannabis industry. Founded in 1901, TEVA’s revenue exceeded $20 billion in 2014. The company is a member of the New York Stock Exchange and since it announced the launch of the TEVA cannabis inhaler, a handful of other companies have joined the movement.
Cannabix Technologies Inc. is one of the companies that has been swayed by the trend. Based in Vancouver, B.C., Cannabix’s team of developers are hard at work creating THC-detecting instruments. It is even possible to test the purity of organic products like cannabis, water, food, and air with the OrganaDx portable food sensor. Equipped with a sensor that measures the level of pesticides contained in solids and liquids, MyDx’s product is a sign of rapid modernization in the marijuana industry.
Cannabis Industry Innovation
The fledgling marijuana market is grasping the attention of companies and investors from all corners. Tech innovation is feeding the budding industry of Israel cannabis, as well as cannabis industries elsewhere. By the year 2020, profit potential for the legal cannabis trade is predicted to hit $21.8 billion. From Flowhub’s seed-to-sale tracking system to GreenRush’s cannabis delivery app, the number of businesses creating software and products for marijuana is growing expeditiously.
Cannabis innovation and legalization has the power to speed up the slow economy, create jobs, and transform the medical world. At present, the industry is worth $7.2 billion, as reported by New Frontier, therefore it is not surprising that so many startups are looking into legal-pot opportunities.
To learn more about new cannabis medical devices and other news, sign-up for our free newsletter using the form to the right.
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.